Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 13/20 | 0.74 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.69 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.69 |
| ▸ | CDK2 | P24941 | 3/20 | 0.64 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.64 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.64 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.60 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29732797 | 1.00 | FLT3 (0.74) | FLT3MAP4K4NTRK1CDK2CCNA2 | |
| SCHEMBL5945653 | 0.88 | FLT3 (0.59) | FLT3MAP4K4NTRK1CDK2CCNA2 | |
| SCHEMBL29732810 | 0.87 | FLT3 (0.73) | FLT3MAP4K4NTRK1CDK2CCNA2 | |
| SCHEMBL28776034 | 0.85 | FLT3 (0.56) | FLT3MAP4K4NTRK1CSNK2A1ROCK1 | |
| SCHEMBL5945722 | 0.84 | FLT3 (0.68) | FLT3MAP4K4NTRK1CDK2CCNA2 | |
| SCHEMBL5945702 | 0.83 | FLT3 (0.61) | FLT3CDK2CCNA2CCNA1CSNK2A1 | |
| SCHEMBL28776022 | 0.82 | FLT3 (0.53) | FLT3MAP4K4NTRK1ROCK1ALDH1A1 | |
| SCHEMBL29732853 | 0.82 | FLT3 (0.53) | FLT3MAP4K4NTRK1ROCK1ALDH1A1 | |
| SCHEMBL29732649 | 0.81 | MAPT (0.61) | FLT3MAP4K4NTRK1CSNK2A1TDP1 | |
| SCHEMBL28776027 | 0.81 | LRRK2 (0.53) | FLT3MAP4K4NTRK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | ASTEX TECHNOLOGY, INC. (GB) | 2006-06-22 | — | — | US | claimed |
| JP-2006500348-A | — | — | 2006-01-05 | — | — | JP | claimed |
| EP-1534685-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | Astex Technology Limited (GB) | 2005-06-01 | — | — | EP | claimed |
| WO-2004014864-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-02-19 | — | — | WO | claimed |
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | ASTEX TECHNOLOGY, INC. (GB) | 2006-06-22 | — | — | US | disclosed |
| EP-1534685-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | Astex Technology Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004014864-A1 | 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135589-A1 | 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors | CCNC, CDK1, CDK7 | FLT3 164/4885MAP4K4 1268/4885NTRK1 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.